Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
Biomarkers
/ blood
COVID-19
/ pathology
Combined Modality Therapy
Critical Care
Female
Humans
Male
Middle Aged
Receptors, Interleukin-6
/ antagonists & inhibitors
Respiration
/ drug effects
Retrospective Studies
SARS-CoV-2
Time Factors
Treatment Outcome
COVID-19 Drug Treatment
Alveolar-arterial oxygen gradient
Chest-X ray
IL-6
Severe COVID-19
Tocilizumab
Vascular score
Journal
Immunology letters
ISSN: 1879-0542
Titre abrégé: Immunol Lett
Pays: Netherlands
ID NLM: 7910006
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
23
10
2020
accepted:
31
10
2020
pubmed:
9
11
2020
medline:
23
12
2020
entrez:
8
11
2020
Statut:
ppublish
Résumé
As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients requiring intensive care were treated with tocilizumab in addition to standard-of-care therapy (SOC) and compared with 13 COVID-19 patients receiving only SOC. Clinical respiratory status, inflammatory markers and vascular radiologic score improved after one week from tocilizumab administration. On the contrary, these parameters were stable or worsened in patients receiving only SOC. Despite major study limitations, improvement of alveolar-arterial oxygen gradient as well as vascular radiologic score after one week may account for improved pulmonary vascular perfusion and could explain the more rapid recovery of COVID-19 patients receiving tocilizumab compared to controls.
Identifiants
pubmed: 33161002
pii: S0165-2478(20)30405-3
doi: 10.1016/j.imlet.2020.10.009
pmc: PMC7644186
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biomarkers
0
Receptors, Interleukin-6
0
tocilizumab
I031V2H011
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
122-128Informations de copyright
Copyright © 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Références
J Infect Dis. 2020 Oct 1;222(9):1444-1451
pubmed: 32601708
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Radiology. 2020 Aug;296(2):E72-E78
pubmed: 32216717
Curr Cardiol Rev. 2008 Aug;4(3):179-92
pubmed: 19936194
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Expert Rev Clin Immunol. 2019 Aug;15(8):813-822
pubmed: 31219357
Int Immunol. 2010 May;22(5):347-52
pubmed: 20410258
Lancet Infect Dis. 2020 Dec;20(12):1365-1366
pubmed: 32359410
J Clin Invest. 2020 Sep 1;130(9):4694-4703
pubmed: 32463803
Chest. 1991 Sep;100(3):762-9
pubmed: 1889270
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Circulation. 2020 Jul 14;142(2):101-104
pubmed: 32369390
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1319-1320
pubmed: 32281885
Crit Rev Oncol Hematol. 2014 Jan;89(1):129-39
pubmed: 24029605
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Lancet Infect Dis. 2020 Oct;20(10):1135-1140
pubmed: 32526193
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Radiol Cardiothorac Imaging. 2020 Jun 18;2(3):e200277
pubmed: 34036264
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Br J Haematol. 2001 Oct;115(1):3-12
pubmed: 11722403
N Engl J Med. 2020 Dec 10;383(24):2333-2344
pubmed: 33085857
JCI Insight. 2020 Sep 3;5(17):
pubmed: 32706339
Chest. 1979 Jun;75(6):748
pubmed: 436542
Immunity. 2020 May 19;52(5):731-733
pubmed: 32325025
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Am J Med. 1994 Jan;96(1):57-62
pubmed: 8304364
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Clin Microbiol Infect. 2021 Feb;27(2):215-227
pubmed: 33161150
Circulation. 2020 Sep 22;142(12):1176-1189
pubmed: 32755393
Front Immunol. 2020 Sep 02;11:2132
pubmed: 32983172
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Clin Chest Med. 1985 Sep;6(3):315-44
pubmed: 3907943
J Allergy Clin Immunol. 2021 Jan;147(1):72-80.e8
pubmed: 33010257
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2575-2581.e2
pubmed: 32565226